Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
AssigneeConnaught Laboratories Limited
InventorLance K. Gordon
Life of this patent
Estimating the term…
Abstract
A water-soluble covalent polysaccharide-diphtheria toxoid conjugate having a molecular weight between 140,000 and 4,500,000 dalton and a ribose/protein ratio between 0.25 and 0.75, capable of producing T-cell dependent antibody response to polysaccharide from H. influenzae b, prepared by mixing a derivatized diphtheria toxoid in a substantially cyanogen halide-free solution with a cyanogen halide-activated capsular H. influenzae b polysaccharide hapten consisting of approximately equal parts of ribose, ribitol and phosphate, which polysaccharide had previously been heat sized until more than 60% attained a molecular size between 200,000 and 2,000,000 dalton.
Claims3
A water-soluble covalent polysaccharide-diphtheria toxoid conjugate
- capable of producing T-cell dependent antibody response to polysaccharide from Haemophilus influenzae b,
- of molecular size above 140,000 and below 4,500,000 dalton, and
- of a ribose/protein ratio between 0.25 and 0.75,
- prepared by mixing adipic hydrazide derivatized diphtheria toxoid in a substantially cyanogen halide-free solution with a cyanogen halide activated capsular Haemophilus influenzae b polysaccharide consisting of approximately equal parts of ribose, ribitol and phosphate, which had previously been sized by heating until more than 60% of the polysaccharide was adjusted to a molecular size between 200,000 and 2,000,000 dalton.
A process for producing a water-soluble covalent polysaccharide-diphtheria toxoid conjugate capable of producing T-cell dependent antibody responsive to polysaccharide from Haemophilus influenzae b
- of molecular size between 140,000 and 4,500,000 dalton, and
- of a ribose/protein ratio between 0.25 and 0.75,
- which comprises
- (a) heating a capsular polysaccharide of Haemophilus influenzae b consisting of approximately equal parts of ribose, ribitol and phosphate until less than 20% is of a molecular size below 200,000 dalton and less than 20% is of a size above 2,000,000 dalton;
- (b) activation of the resulting sized polysaccharide with cyanogen bromide;
- (c) removal of substantially all the unreacted cyanogen bromide;
- and
- (d) agitation of the activated product with adipic hydrazide derivatized diphtheria toxoid.
Dependencies are inferred from the claim text.